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Williams et al., page 238
If you’ve ever imputed genotypes, performed identity-by-
descent analysis, or tried to identify signals of selection,
you understand the importance of phased haplotypes.
Although many methods for haplotype inference are
available, they all demand large computational resources.
With the increasing size of data sets available for analysis,
it is becoming ever more important to factor in the
amount of required computing power when such studies
are designed. In this issue, Williams et al. describe a new
method, termed HAPI-UR (haplotype inference for unre-
lated samples), that is capable of rapidly phasing data
sets with 100,000 samples; although this size seems
almost unthinkable now, it will most likely become
commonplace in the not-too-distant future. Compared
with other popular methods, including Beagle, MaCH,
IMPUTE2, and SHAPEIT, HAPI-UR runs faster and has
a lower error rate. Beyond describing their method, the
authors also show that phasing is most accurate when
samples from individuals across ethnicities are grouped
together rather than in batches. Given how widespread
the use of other phasing programs has become, it seems
that many investigators will be HAPI-ly asking tough ques-
tions that are able to be answered only through the anal-
ysis of very large data sets.Really Rare Variants
Heinzen et al., page 293; Need et al., page 303
Mendelian disorders, so the story goes, are the low-
hanging fruit; the real challenge will be identifying vari-
ants that underlie the genetic architecture of complex
diseases. For many years, geneticists relied on genome-
wide association studies (GWASs) to identify common vari-
ants that increase susceptibility of complex disorders by
figuring that common conditions would be caused by
common alleles. However, after the initial GWAS excite-
ment, many have suggested that the ‘‘missing heritability’’
problem might only be solved by the identification of rare
variants with large effects. Advances in next-generation
sequencing allow such an approach to be considered,
and many statistical methods have been proposed for the
identification of pathogenic variants in the midst of large
amounts of sequencing data; however, the discussion has1Deputy Editor, AJHG
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The Americremained quite theoretical. In this issue, Heinzen et al.
and Need et al. investigate the practicality of this approach
through the analysis of large cohorts of individuals with
epilepsy and schizophrenia, respectively. Both studies
identify variants unique to cases, but none of these vari-
ants achieve genome-wide significance. What does this
mean for the search for rare variants? Very large cohorts
are probably needed—in some cases, cohorts larger than
will ever be feasible. Therefore, it’s back to the laboratory,
where experimentation will be needed for addressing ques-
tions of pathogenicity. The challenge then, as with the
GWAS approach, will be prioritizing variants for follow-
up studies.Quite a FUS about Essential Tremor
Merner et al., page 313
Essential tremor (ET) is estimated to be one of the most
common adult-onset movement disorders, but suspicions
about overdiagnosis have made it difficult to pin down
causative mutations. Now, through the use of exome
sequencing, Merner et al. find that mutations in FUS cause
ET. Notably, FUSmutations have also been identified as the
cause of amyotrophic lateral sclerosis (ALS, also known as
Lou Gehrig disease), a fatal neuromuscular disorder;
however, the mechanism has remained elusive. Through
experiments aimed at gaining a better understanding of
the phenotypic heterogeneity seen in FUS mutations, the
authors found that whereas ET mutant mRNAs undergo
nonsense-mediated mRNA decay, mutant mRNAs associ-
ated with ALS do not. Mutant versions of FUS have been
identified in cells from individuals affected by ALS, lending
support to the idea that this class of mutation produces
a mature protein product. The allelic nature of these two
divergent movement disorders is unexpected, and further
research will be required for determining what role is
played by modifier polymorphisms. In addition, in-depth
characterization in model systems will help to clarify the
function of FUS and the effects of disease-related
mutations.Acting Up, Upstream
Cho et al., page 343; Semler et al., page 349
In the hunt for alleles that cause Mendelian disorders,
whole-exome sequencing has become the technique ofy of Human Genetics. All rights reserved.
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choice. This method, however, will necessarily miss muta-
tions that occur outside of the coding sequence, even those
that lie just a few nucleotides out of reach. In this issue,
Cho et al. and Semler et al. identify in the 50 UTR of IFITM5
a single recurrent de novo mutation that causes osteogen-
esis imperfecta type V. This nucleotide change, located 14
bases upstream of the start codon, introduces a new in-
frame start codon that creates a new protein product
with five additional N-terminal amino acids. This muta-
tion, which might well have been hiding in plain sight
during other sequencing projects, was identified across
populations and appears to confer a gain of function to
the protein. A clear understanding of the pathogenic
nature of this mutation requires further experimentation,
but the authors suggest that altered posttranslational
modification might be at play. Although investigators
often focus on mutations that create premature trunca-
tions, this finding serves as a reminder that mutations
can (and do) occur throughout the genome and that
Sanger sequencing will be unable to detect several classes
of mutations. It also draws much needed attention to the
fact that the 50 UTR is not simply a home to transcrip-
tion-factor binding sites but is also a repository of genetic
variation.212 The American Journal of Human Genetics 91, 211–212, August 1Malignant De Novo CNVs
Stadler et al., page 379
As many families can attest, there is a significant hereditary
component to several early-onset cancers. But for others,
including testicular germ cell tumors (TGCTs), the most
common solid tumor type in youngmales, the genetic cause
of the malignancy remains far from clear. Stadler et al.
posited that copy-number variants (CNVs) might play
a causative role in this class of cancers, and in this issue,
they show that the rate of de novo CNVs in TGCTs exceeds
that which could be expected by chance alone. The identi-
fiedCNVs spanned areas greater than 100 kb and comprised
both insertion and deletion events. By contrast, such
apatternwasnotobserved insimplexcasesofbreastorcolon
cancer.Whatmakes TGCTs different is not entirely clear just
yet, but the cell type of origin certainly could be a key factor.
Although further studies will be needed for uncovering any
genetic patterns that might be present in TGCT CNVs, this
study strongly suggests that, much like in cardiovascular
disease and autism spectrum disorders, de novo CNVs play
a causative role in the etiology of TGCTs. Armed with this
information, patients and clinicians have a new weapon
for the diagnosis and treatment of this disease.0, 2012
